CELLULARLINE SPA (CELL.MI) Fundamental Analysis & Valuation

BIT:CELL • IT0005244618

Current stock price

2.29 EUR
-0.04 (-1.72%)
Last:

This CELL.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. CELL.MI Profitability Analysis

1.1 Basic Checks

  • In the past year CELL was profitable.
  • CELL had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: CELL reported negative net income in multiple years.
  • In the past 5 years CELL always reported a positive cash flow from operatings.
CELL.MI Yearly Net Income VS EBIT VS OCF VS FCFCELL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • The Return On Assets of CELL (3.22%) is comparable to the rest of the industry.
  • CELL has a Return On Equity of 5.15%. This is in the better half of the industry: CELL outperforms 62.50% of its industry peers.
  • CELL's Return On Invested Capital of 6.27% is in line compared to the rest of the industry. CELL outperforms 59.38% of its industry peers.
Industry RankSector Rank
ROA 3.22%
ROE 5.15%
ROIC 6.27%
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
CELL.MI Yearly ROA, ROE, ROICCELL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

  • CELL's Profit Margin of 2.90% is in line compared to the rest of the industry. CELL outperforms 50.00% of its industry peers.
  • CELL's Profit Margin has declined in the last couple of years.
  • CELL has a Operating Margin (4.75%) which is in line with its industry peers.
  • CELL's Operating Margin has declined in the last couple of years.
  • CELL has a Gross Margin of 40.71%. This is comparable to the rest of the industry: CELL outperforms 56.25% of its industry peers.
  • CELL's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 4.75%
PM (TTM) 2.9%
GM 40.71%
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
CELL.MI Yearly Profit, Operating, Gross MarginsCELL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CELL.MI Health Analysis

2.1 Basic Checks

  • CELL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • CELL has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CELL has less shares outstanding
  • The debt/assets ratio for CELL has been reduced compared to a year ago.
CELL.MI Yearly Shares OutstandingCELL.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CELL.MI Yearly Total Debt VS Total AssetsCELL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 2.76 indicates that CELL is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • CELL has a better Altman-Z score (2.76) than 65.63% of its industry peers.
  • CELL has a debt to FCF ratio of 2.13. This is a good value and a sign of high solvency as CELL would need 2.13 years to pay back of all of its debts.
  • The Debt to FCF ratio of CELL (2.13) is better than 71.88% of its industry peers.
  • A Debt/Equity ratio of 0.11 indicates that CELL is not too dependend on debt financing.
  • CELL has a better Debt to Equity ratio (0.11) than 78.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 2.13
Altman-Z 2.76
ROIC/WACC0.69
WACC9.15%
CELL.MI Yearly LT Debt VS Equity VS FCFCELL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 2.14 indicates that CELL has no problem at all paying its short term obligations.
  • CELL has a better Current ratio (2.14) than 75.00% of its industry peers.
  • A Quick Ratio of 1.37 indicates that CELL should not have too much problems paying its short term obligations.
  • With a decent Quick ratio value of 1.37, CELL is doing good in the industry, outperforming 71.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 1.37
CELL.MI Yearly Current Assets VS Current LiabilitesCELL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CELL.MI Growth Analysis

3.1 Past

  • CELL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.72%, which is quite good.
  • The earnings per share for CELL have been decreasing by -20.43% on average. This is quite bad
  • Looking at the last year, CELL shows a decrease in Revenue. The Revenue has decreased by -1.25% in the last year.
  • Measured over the past years, CELL shows a small growth in Revenue. The Revenue has been growing by 3.18% on average per year.
EPS 1Y (TTM)17.72%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-2.95%
Revenue 1Y (TTM)-1.25%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-5.3%

3.2 Future

  • Based on estimates for the next years, CELL will show a small growth in Earnings Per Share. The EPS will grow by 2.47% on average per year.
  • Based on estimates for the next years, CELL will show a decrease in Revenue. The Revenue will decrease by -0.60% on average per year.
EPS Next Y-15%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-6.17%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CELL.MI Yearly Revenue VS EstimatesCELL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
CELL.MI Yearly EPS VS EstimatesCELL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

7

4. CELL.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 6.94, the valuation of CELL can be described as very cheap.
  • Based on the Price/Earnings ratio, CELL is valued cheaply inside the industry as 90.63% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of CELL to the average of the S&P500 Index (25.23), we can say CELL is valued rather cheaply.
  • A Price/Forward Earnings ratio of 5.35 indicates a rather cheap valuation of CELL.
  • Based on the Price/Forward Earnings ratio, CELL is valued cheaper than 96.88% of the companies in the same industry.
  • CELL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.28.
Industry RankSector Rank
PE 6.94
Fwd PE 5.35
CELL.MI Price Earnings VS Forward Price EarningsCELL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • 96.88% of the companies in the same industry are more expensive than CELL, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, CELL is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 3.32
EV/EBITDA 2.34
CELL.MI Per share dataCELL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.47%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. CELL.MI Dividend Analysis

5.1 Amount

  • CELL has a Yearly Dividend Yield of 4.70%, which is a nice return.
  • Compared to an average industry Dividend Yield of 1.08, CELL pays a better dividend. On top of this CELL pays more dividend than 93.75% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, CELL pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.7%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 28.17% of the earnings are spent on dividend by CELL. This is a low number and sustainable payout ratio.
DP28.17%
EPS Next 2Y2.47%
EPS Next 3YN/A
CELL.MI Yearly Income VS Free CF VS DividendCELL.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M
CELL.MI Dividend Payout.CELL.MI Dividend Payout, showing the Payout Ratio.CELL.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

CELL.MI Fundamentals: All Metrics, Ratios and Statistics

CELLULARLINE SPA

BIT:CELL (3/20/2026, 7:00:00 PM)

2.29

-0.04 (-1.72%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)03-09
Earnings (Next)05-05
Inst Owners4.94%
Inst Owner ChangeN/A
Ins Owners19.57%
Ins Owner ChangeN/A
Market Cap50.08M
Revenue(TTM)237.30M
Net Income(TTM)6.89M
Analysts82.86
Price Target4.18 (82.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.7%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP28.17%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 6.94
Fwd PE 5.35
P/S 0.21
P/FCF 3.32
P/OCF 2.51
P/B 0.37
P/tB 0.86
EV/EBITDA 2.34
EPS(TTM)0.33
EY14.41%
EPS(NY)0.43
Fwd EY18.71%
FCF(TTM)0.69
FCFY30.16%
OCF(TTM)0.91
OCFY39.89%
SpS10.85
BVpS6.11
TBVpS2.65
PEG (NY)N/A
PEG (5Y)N/A
Graham Number6.74
Profitability
Industry RankSector Rank
ROA 3.22%
ROE 5.15%
ROCE 7.16%
ROIC 6.27%
ROICexc 7.42%
ROICexgc 17.24%
OM 4.75%
PM (TTM) 2.9%
GM 40.71%
FCFM 6.37%
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y46.34%
ROICexgc growth 5Y-17.53%
ROICexc growth 3Y77.77%
ROICexc growth 5Y-8.95%
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
F-Score7
Asset Turnover1.11
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 2.13
Debt/EBITDA 0.57
Cap/Depr 35.76%
Cap/Sales 2.05%
Interest Coverage 2.61
Cash Conversion 80.21%
Profit Quality 219.21%
Current Ratio 2.14
Quick Ratio 1.37
Altman-Z 2.76
F-Score7
WACC9.15%
ROIC/WACC0.69
Cap/Depr(3y)26.8%
Cap/Depr(5y)35.01%
Cap/Sales(3y)3.22%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.72%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-2.95%
EPS Next Y-15%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.25%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-5.3%
Revenue Next Year-6.17%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.14%
EBIT growth 3Y54.08%
EBIT growth 5Y-17%
EBIT Next Year25.99%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y155.95%
FCF growth 3Y4.84%
FCF growth 5Y6.28%
OCF growth 1Y84.91%
OCF growth 3Y4.12%
OCF growth 5Y1.2%

CELLULARLINE SPA / CELL.MI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CELLULARLINE SPA (CELL.MI) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CELL.MI.


What is the valuation status for CELL stock?

ChartMill assigns a valuation rating of 7 / 10 to CELLULARLINE SPA (CELL.MI). This can be considered as Undervalued.


What is the profitability of CELL stock?

CELLULARLINE SPA (CELL.MI) has a profitability rating of 3 / 10.


What are the PE and PB ratios of CELLULARLINE SPA (CELL.MI) stock?

The Price/Earnings (PE) ratio for CELLULARLINE SPA (CELL.MI) is 6.94 and the Price/Book (PB) ratio is 0.37.


Can you provide the dividend sustainability for CELL stock?

The dividend rating of CELLULARLINE SPA (CELL.MI) is 6 / 10 and the dividend payout ratio is 28.17%.